Physician profile
Mohammed R Al-Najjar
NPI 1972524338
$585,648.05
in general payments reported to CMS, 2019-2025
56 companies · $85K in 2025
The $85K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110K · 2020: $63K · 2021: $79K · 2022: $102K · 2023: $89K · 2024: $57K · 2025: $85K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $191K · Travel and Lodging: $13K · Food and Beverage: $12K · Honoraria: $9,000 · Consulting Fee: $5,555 · Education: $29.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $190,759.72 |
| Travel and Lodging | $12,921.43 |
| Food and Beverage | $12,411.69 |
| Honoraria | $9,000.00 |
| Consulting Fee | $5,555.00 |
| Education | $29.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $131,713.62 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Amgen INC. | $121,700.29 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $84,962.07 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $56,446.42 | 2019-2024 | Farxiga, Airsupra, Imfinzi |
| Sanofi-Aventis U.S. LLC | $52,477.87 | 2019-2023 | |
| Abbott Laboratories | $27,832.11 | 2020-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $27,368.20 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $21,468.95 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Allergan, INC. | $16,336.87 | 2019-2021 | |
| Esperion Therapeutics, INC. | $11,882.78 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $11,855.79 | 2019-2024 | Spravato, Xarelto |
| Axsome Therapeutics, INC. | $10,345.92 | 2023-2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $5,922.59 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $746.92 | 2022-2025 | |
| Glaxosmithkline, LLC. | $608.59 | 2019-2024 | Trelegy Ellipta, Nucala |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Al-Najjar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.